Comparison of gentamicin pharmacokinetic parameters determined by fluorescence polarization immunoassay and latex agglutination methods. 1994

K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
St. Paul-Ramsey Medical Center, Section of Clinical Pharmacy, MN 55101-2595.

Fluorescence polarization immunoassay (FPIA) (TDx, Abbott Laboratories Diagnostics, Irvin, TX, U.S.A.) is commonly utilized for quantitative determination of gentamicin serum concentrations. Recently, automated homogeneous latex agglutination (LA) (Technicon Immuno-1, Miles Diagnostics Division, Tarrytown, NY, U.S.A.) for the quantitative determination of gentamicin serum concentrations has been approved for commercial use. The purpose of this study was to determine whether gentamicin serum concentration-time data from the same patients assayed by FPIA and LA would produce the same estimates for half-life, elimination rate constant, distribution volume, drug clearance, dosage interval, and dose. A total of 70 pre- and postinfusion serum samples were obtained from 19 patients. Each sample was divided into two aliquots; one was assayed by FPIA and the other by LA. The correlation coefficient between the two assay methods was 0.99 (y = 1.03x - 0.05). The mean differences for half-life, volume of distribution, elimination rate constant, total body clearance, and gentamicin dosage were 0.13, 0.32, 0.66, -0.99, and 0.03%, respectively. No statistically significant differences were seen in calculated gentamicin pharmacokinetic parameters (p < 0.05). Pharmacokinetic parameters and dosage recommendations derived from FPIA and the LA assay using pre- and postinfusion serum concentration-time data appear interchangeable and do not result in differences between gentamicin dosing regimens.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007841 Latex Fixation Tests Passive agglutination tests in which antigen is adsorbed onto latex particles which then clump in the presence of antibody specific for the adsorbed antigen. (From Stedman, 26th ed) Latex Agglutination Tests,Agglutination Test, Latex,Agglutination Tests, Latex,Fixation Test, Latex,Fixation Tests, Latex,Latex Agglutination Test,Latex Fixation Test,Test, Latex Agglutination,Test, Latex Fixation,Tests, Latex Agglutination,Tests, Latex Fixation
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
January 1983, Therapeutic drug monitoring,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
January 1987, Therapeutic drug monitoring,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
October 1982, Antimicrobial agents and chemotherapy,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
April 1987, Methods and findings in experimental and clinical pharmacology,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
August 1986, Rinsho byori. The Japanese journal of clinical pathology,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
January 1985, Therapeutic drug monitoring,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
March 1989, Clinical chemistry,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
January 1990, Journal - Association of Official Analytical Chemists,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
June 1980, American journal of clinical pathology,
K J Madaras-Kelly, and S Mihalovic, and D Zittel, and D Ehresman, and D J Lakatua, and J C Rotschafer
January 1991, Transfusion,
Copied contents to your clipboard!